Item 8.01 Other Events.
On September 13, 2022, Eton Pharmaceuticals, Inc. issued a press release
announcing that it had acquired betaine anhydrous for oral solution.
Under terms of the agreement, Eton paid the seller $2.0 million upon signing for
the acquisition and all existing inventory, and will pay to the seller 35% of
product profits for a period of ten years, plus potential contingent payments of
up to an additional $1.0 million, including:
? $0.25 million on the twelve month anniversary of closing
? $0.25 million when net sales of the product exceed $4.0 million in a calendar
year
? $0.50 million if no additional generic competitors have launched within 48
months after closing
A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 Press Release dated September 13, 2022
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
2
© Edgar Online, source Glimpses